aptaTargets CSO Macarena Hernández will speak at the 10th European Stroke Conference

6 May, 2024

aptaTargets - ESOC 2024
aptaTargets, a clinical stage biopharmaceutical company focused on the discovery and development of novel therapies based on aptamer technology for targeting acute diseases where inflammation causes significant damage with high unmet medical need, announces that its Chief Scientific Officer (CSO), Dr. Macarena Hernández, will be one of the speakers at the European Stroke Conference (ESOC) from 15 to 17 May 2024 in Basel, Switzerland.

ESOC is Europe’s leading forum for advances in research and the clinical care of patients with cerebrovascular diseases. This year, ESOC celebrates its tenth edition and will bring together more than 4,000 researchers, physicians and C-level executives from the biomedical industry from 96 countries.

Dr. Macarena Hernández will present at the session titled Tackling the Inflammation: The APRIL group, which will take place on Wednesday, 15 May at 3:50 pm local time.

aptaTargets has developed ApTOLL, a first-in-class cytoprotective drug that acts on the Toll-like receptor 4 (TLR4), blocking the inflammatory response that occurs after an ischemic stroke. This innovation has earned it the PRIME designation from the European Medicines Agency (EMA).

During her presentation, Dr. Macarena Hernández will explain the progress made by ApTOLL in treating patients with acute ischemic stroke backed by the APRIL Phase 1b/2a clinical trial that has demonstrated a decrease in mortality from 18% to 5% compared to the placebo arm, as well as a significant decrease in disability at 3 months after stroke onset. This year 2024, the company plans to initiate the Phase 2b trial.

In addition to the comprehensive APRIL clinical trial that aims to demonstrate the efficacy and safety of ApTOLL in patients who have suffered an ischemic stroke, aptaTargets is also leading the RACETOLL Phase 2a clinical trial with stroke patients who are administered ApTOLL in ambulances. RACETOLL has received funding from the Government of Spain.